Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D03MYO
|
||||
Former ID |
DIB001166
|
||||
Drug Name |
MGL-3196
|
||||
Indication | Hyperlipidaemia [ICD9: 272.0-272.4; ICD10:E78] | Phase 1 | [1] | ||
Company |
Madrigal pharmaceuticals
|
||||
Structure |
![]() |
Download2D MOL |
|||
Target and Pathway | |||||
Target(s) | Thyroid hormone receptor beta-1 | Target Info | Agonist | [1] | |
KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
Thyroid hormone signaling pathway | |||||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
Reactome | Nuclear Receptor transcription pathway | ||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Hematopoietic Stem Cell Differentiation | |||||
Nuclear Receptors | |||||
References | |||||
REF 1 | Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.